Gupta Gauree, Lautenbach Ebbing, Lewis James D
Center for Clinical Epidemiology and Biostatistics, Department of Internal Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104-6021, USA.
Clin Gastroenterol Hepatol. 2006 Dec;4(12):1483-90. doi: 10.1016/j.cgh.2006.09.019.
BACKGROUND & AIMS: An increased risk of herpes zoster in patients with inflammatory bowel disease (IBD) is hypothesized based on altered immune function, especially among patients receiving immunosuppressive medications.
We performed a retrospective cohort study and a retrospective nested case-control study using 1988-1997 data from the General Practice Research Database. In the cohort study, 7823 Crohn's disease (CD) and 11,930 ulcerative colitis (UC) patients were matched on age, sex, and primary care practice to 79,563 randomly selected controls without CD or UC. In the nested case-control study, 185 CD patients with zoster and 266 UC patients with zoster were matched on sex and year of birth to 1787 IBD patients without zoster.
In the cohort study, the incidence of zoster was higher in patients with CD and UC compared with their matched controls (UC incidence rate ratio, 1.21; 95% confidence interval [CI], 1.05-1.40; CD incidence rate ratio, 1.61; 95% CI, 1.35-1.92). In the nested case-control study, receipt of a prescription for corticosteroids (adjusted odds ratio, 1.5; 95% CI, 1.1-2.2) or azathioprine/6-mercaptopurine (adjusted odds ratio, 3.1; 95% CI, 1.7-5.6) were both associated with zoster.
Patients with IBD, especially those on immunosuppressive medications, are at higher risk for herpes zoster compared with the general population. Future studies should clarify the relative risk associated with anti-tumor necrosis factor alpha therapies and determine the use of the new zoster vaccine for patients with IBD.
基于免疫功能改变,推测炎症性肠病(IBD)患者发生带状疱疹的风险增加,尤其是接受免疫抑制药物治疗的患者。
我们使用来自全科医学研究数据库1988 - 1997年的数据进行了一项回顾性队列研究和一项回顾性巢式病例对照研究。在队列研究中,将7823例克罗恩病(CD)患者和11930例溃疡性结肠炎(UC)患者按年龄、性别和基层医疗实践与79563例随机选择的无CD或UC的对照进行匹配。在巢式病例对照研究中,将185例患带状疱疹的CD患者和266例患带状疱疹的UC患者按性别和出生年份与1787例未患带状疱疹的IBD患者进行匹配。
在队列研究中,CD和UC患者的带状疱疹发病率高于其匹配的对照(UC发病率比,1.21;95%置信区间[CI],1.05 - 1.40;CD发病率比,1.61;95%CI,1.35 - 1.92)。在巢式病例对照研究中,接受皮质类固醇处方(校正比值比,1.5;95%CI,1.1 - 2.2)或硫唑嘌呤/6 - 巯基嘌呤(校正比值比,3.1;95%CI,1.7 - 5.6)均与带状疱疹相关。
与普通人群相比,IBD患者,尤其是接受免疫抑制药物治疗的患者,发生带状疱疹的风险更高。未来的研究应阐明与抗肿瘤坏死因子α治疗相关的相对风险,并确定IBD患者使用新型带状疱疹疫苗的情况。